At least 70% of all breast biopsies require site identifiers with more than 800,000 used every year in the United States. Single breast, multiple lesion biopsies are performed at different percentage rates depending on the imaging modality used in the biopsy. It is estimated that in a single breast, multiple biopsies are performed 10% of the time using ultrasound guidance, 5% in stereotactic x-ray and 40% with MRI-guided breast biopsy.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. For more information, visit www.hologic.com. Suros breast biopsy devices are patient focused, physician-inspired “Compassionate Technologies.” The Suros ATEC (Automated Tissue Excision and Collection) product line is compatible with stereotactic x-ray, ultrasound and magnetic resonance imaging (MRI) systems. The Suros Celero is an ultrasound-only breast biopsy device. Suros pioneered and is the market leader in MRI-guided breast biopsy technology for high-risk women. For more information about the Suros family of breast biopsy devices, visit www.SurosSurgical.com.